首页> 外文期刊>Science >E protein silencing by the leukemogenic AML1-ETO fusion protein
【24h】

E protein silencing by the leukemogenic AML1-ETO fusion protein

机译:致白血病的AML1-ETO融合蛋白使E蛋白沉默

获取原文
获取原文并翻译 | 示例
       

摘要

The AML1-ETO fusion protein, generated by the t(8;21) chromosomal translocation, is causally involved in nearly 15% of acute myeloid leukemia (AML) cases. This study shows that AML1-ETO, as well as ETO, inhibits transcriptional activation by E proteins through stable interactions that preclude recruitment of p300/CREB-binding protein (CBP) coactivators. These interactions are mediated by a conserved ETO TAF4 homology domain and a 17-amino acid p300/CBP and ETO target motif within AD1 activation domains of E proteins. In t(8;21) leukemic cells, very stable interactions between AML1-ETO and E proteins underlie a t(8;21) translocation-specific silencing of E protein function through an aberrant cofactor exchange mechanism. These studies identify E proteins as AML1-ETO targets whose dysregulation may be important for t(8;21) leukemogenesis, as well as an E protein silencing mechanism that is distinct from that associated with differentiation-inhibitory proteins.
机译:由t(8; 21)染色体易位产生的AML1-ETO融合蛋白与近15%的急性髓细胞白血病(AML)病例有因果关系。这项研究表明AML1-ETO以及ETO通过稳定的相互作用抑制E蛋白的转录激活,从而阻止了p300 / CREB结合蛋白(CBP)共激活子的募集。这些相互作用由保守的ETO TAF4同源结构域和E蛋白AD1激活结构域内的17个氨基酸p300 / CBP和ETO靶基序介导。在t(8; 21)白血病细胞中,AML1-ETO与E蛋白之间非常稳定的相互作用是通过异常辅因子交换机制使E蛋白功能发生t(8; 21)易位特异性沉默的基础。这些研究确定E蛋白为AML1-ETO靶标,其失调对t(8; 21)白血病的发生可能很重要,以及与分化抑制蛋白相关的E蛋白沉默机制也不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号